First Time Loading...

Sangamo Therapeutics Inc
NASDAQ:SGMO

Watchlist Manager
Sangamo Therapeutics Inc Logo
Sangamo Therapeutics Inc
NASDAQ:SGMO
Watchlist
Price: 0.6702 USD 7.28% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

SGMO's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. [ Read More ]

The intrinsic value of one SGMO stock under the Base Case scenario is 1.9809 USD. Compared to the current market price of 0.6702 USD, Sangamo Therapeutics Inc is Undervalued by 66%.

Key Points:
SGMO Intrinsic Value
Base Case
1.9809 USD
Undervaluation 66%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Sangamo Therapeutics Inc

Backtest SGMO Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling SGMO stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Significant Advances and Financial Prudence
2023-Q4 Earnings Call

Significant Advances and Financial Prudence

The company has preclinical models suggesting a breakthrough in treating diseases like prion and tauopathies such as Alzheimer's, with the potential to extend life. They plan to submit a clinical trial authorization (CTA) in the UK in Q4 2025 due to its robust prion disease infrastructure. Additionally, a resumption of their tau program is anticipated, also in Q4 2025, aiming at disorders like Parkinson's. Financially, they've slashed operational spending by half, ending 2023 with $81 million, sufficient to last into Q3 2024. They forecast operating expenses for 2024 to be between $125 million and $145 million, decreasing to below $105 million in 2025. Advanced capsid STAC-BBB outshines others by a notable 700-fold in brain enrichment, vital for treating neurological disorders.

Financials

Balance Sheet Decomposition
Sangamo Therapeutics Inc

Current Assets 94.3m
Cash & Short-Term Investments 81m
Receivables 1.3m
Other Current Assets 12m
Non-Current Assets 71m
PP&E 52.9m
Other Non-Current Assets 18.1m
Current Liabilities 47.7m
Accounts Payable 15.3m
Accrued Liabilities 32.5m
Non-Current Liabilities 34.7m
Other Non-Current Liabilities 34.7m
Efficiency

Earnings Waterfall
Sangamo Therapeutics Inc

Revenue
176.2m USD
Operating Expenses
-278.8m USD
Operating Income
-102.6m USD
Other Expenses
-155.2m USD
Net Income
-257.8m USD

Free Cash Flow Analysis
Sangamo Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

SGMO Profitability Score
Profitability Due Diligence

Sangamo Therapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

Exceptional 1-Year Revenue Growth
Positive 3-Years Revenue Growth
Declining ROIC
Declining ROE
16/100
Profitability
Score

Sangamo Therapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

SGMO Solvency Score
Solvency Due Diligence

Sangamo Therapeutics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
51/100
Solvency
Score

Sangamo Therapeutics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SGMO Price Targets Summary
Sangamo Therapeutics Inc

Wall Street analysts forecast SGMO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SGMO is 3.23 USD with a low forecast of 1.01 USD and a high forecast of 8.4 USD.

Lowest
Price Target
1.01 USD
51% Upside
Average
Price Target
3.23 USD
382% Upside
Highest
Price Target
8.4 USD
1 153% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

SGMO Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

SGMO Price
Sangamo Therapeutics Inc

1M 1M
-42%
6M 6M
+12%
1Y 1Y
-62%
3Y 3Y
-94%
5Y 5Y
-93%
10Y 10Y
-96%
Annual Price Range
0.6702
52w Low
0.3
52w High
1.76
Price Metrics
Average Annual Return -7.69%
Standard Deviation of Annual Returns 70.59%
Max Drawdown -98%
Shares Statistics
Market Capitalization 119.4m USD
Shares Outstanding 178 906 000
Percentage of Shares Shorted 6.61%

SGMO Return Decomposition
Main factors of price return

What is price return decomposition?

SGMO News

Other Videos

Company Profile

Sangamo Therapeutics Inc Logo
Sangamo Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

119.4m USD

Dividend Yield

0%

Description

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Brisbane California, California and currently employs 431 full-time employees. The company went IPO on 2000-04-06. The firm focuses on leveraging its optimized zinc finger (ZF) technology, which is a differentiated tool used to develop genomic medicines, including allogeneic cell therapies and in vivo genome engineering therapies. Its product candidates include Isaralgagene civaparvovec, also known as ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, its ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease (SCD); TX200, its wholly owned Chimeric Antigen Receptor (CAR) engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.

Contact

CALIFORNIA
Brisbane California
7000 Marina Blvd
+15109706000.0
https://www.sangamo.com/

IPO

2000-04-06

Employees

431

Officers

CEO, President & Director
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
Senior VP, CFO & Principal Accounting Officer
Ms. Prathyusha Duraibabu CPA, M.B.A.
Head of Research
Ms. Amy Pooler Ph.D.
Head of Technology
Mr. Gregory Davis Ph.D.
Head of Corporate Communications & Investor Relations Officer
Ms. Aron Feingold
Senior VP, General Counsel & Corporate Secretary
Mr. Scott B. Willoughby
Show More
Senior VP & Chief Development Officer
Dr. Nathalie Dubois-Stringfellow Ph.D.
Chief Medical Officer
Dr. Lisa Rojkjaer M.D.
Head of Technical Operations
Phillip Ramsey
Head of Business Development & Alliance Management
Ms. Stephanie J. Seiler CLP
Show Less

See Also

Discover More
What is the Intrinsic Value of one SGMO stock?

The intrinsic value of one SGMO stock under the Base Case scenario is 1.9809 USD.

Is SGMO stock undervalued or overvalued?

Compared to the current market price of 0.6702 USD, Sangamo Therapeutics Inc is Undervalued by 66%.